Spyre Shares Slide After Insider Sell-Off
Shares of Spyre Therapeutics plunged in premarket trading on June 24 after investors reacted to a massive insider stock sale involving one of the company’s largest affiliated shareholders. The biotechnology company’s stock dropped nearly 14% before the opening bell, reflecting concerns about insider confidence and future share performance. $400 Million Worth of Shares Sold The…